Protective Effect of Epigallocatechin-3-Gallate Against Fructose-Induced Metabolic Associated Fatty Liver Disease in Mice by Regulating Ferroptosis and Autophagy via SIRT5.
Metabolic dysfunction-associated fatty liver disease (MAFLD) lacks effective pharmacological therapies and is strongly associated with excessive fructose consumption. Ferroptosis and autophagy dysregulation are increasingly recognized as key drivers of MAFLD progression. Epigallocatechin-3-gallate (EGCG) exerts hepatop...